English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Global: Zendy Plus annual

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Global: Zendy Tools annual

Global: Zendy Free Plan

Global: Zendy Tools monthly

Global: Zendy Plus monthly

Marcin Wojtera1, Tomasz Sobów2 © Medical Communications Sp. z o.o. This is an open-access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives License (CC BY-NC-ND). Reproduction is permitted for personal, educational, non-commercial use, provided that the original article is in whole, unmodified, and properly cited. Received: 16.02.2018 Accepted: 18.02.2018 Published: 29.03.2018 © Psychiatr Psychol Klin 2018, 18 (1), p. 74–80 DOI: 10.15557/PiPK.2018.0010 Duloksetyna – profil farmakologiczny i kliniczny leku z grupy inhibitorów zwrotnego wychwytu serotoniny i noradrenaliny Duloxetine: the pharmacological and clinical profile of a drug from the group of serotonin and noradrenaline reuptake inhibitors